ライフサイエンスコーパス: tobacco use

1 d risk factors for NCDs (such as obesity and tobacco use).

2 amily history, obesity, type 2 diabetes, and tobacco use.

3 male sex, white race, abdominal obesity, and tobacco use.

4 s tobacco use, and 27.1% (22.8-31.7) for any tobacco use.

5 t class analysis indicated 5 classes of poly-tobacco use.

6 etes, and 19.4% reported current or previous tobacco use.

7 re, both forms of disease are exacerbated by tobacco use.

8 ntation of evidence-based measures to reduce tobacco use.

9 bidities, physical activity, and alcohol and tobacco use.

10 n phenotypes, including hypercoagulation and tobacco use.

11 arkinson's disease and a person's history of tobacco use.

12 106 never exposed, matched for age, sex, and tobacco use.

13 ables after adjusting for sex, diabetes, and tobacco use.

14 yzing the impact of pre transplant recipient tobacco use.

15 of negative events increases with increasing tobacco use.

16 guard future generations from the ravages of tobacco use.

17 nt effective public health policies limiting tobacco use.

18 ovascular risk factors, including especially tobacco use.

19 re paradigm that may better model adolescent tobacco use.

20 some regions for years of cocaine and daily tobacco use.

21 systemic inflammation, pericardial fat, and tobacco use.

22 than currently agreed should be adopted for tobacco use.

23 early age of initiation for both alcohol and tobacco use.

24 gets for all three of these measures and for tobacco use.

25 , in many cases cannabis use develops before tobacco use.

26 h-burden countries for both tuberculosis and tobacco use.

27 l, high-density lipoprotein cholesterol, and tobacco use.

28 sex, body mass index, recent infection, and tobacco use.

29 forts to reduce morbidity and mortality from tobacco use.

30 drawal may have a critical role in promoting tobacco use.

31 ving diet, increasing activity, and reducing tobacco use.

32 bits, increase physical activity, and reduce tobacco use.

33 n other physiological effects of smoking and tobacco use.

34 a diagnosis of bladder cancer on patterns of tobacco use.

35 etes, and 19.4% reported current or previous tobacco use.

36 symptoms representing a major burden to quit tobacco use.

37 omote novel therapeutic strategies to reduce tobacco use.

38 e considered a safe alternative to combusted tobacco use.

39 population health consequences of continued tobacco use.

40 ntial adverse health effects of this form of tobacco use.

41 Rs) of OPC, genital HPV in healthy women, or tobacco use.

42 the acceleration of biological aging due to tobacco use.

43 r-specific mortality risks of dual- and poly-tobacco use.

44 bacco use, and 3.6% (95% CI 2.3-5.2) for any tobacco use.

45 increased age, prior radiation therapy, and tobacco use.

46 oth toxicants and carcinogens resulting from tobacco use.

47 us cerebrovascular disease) + 0.352 x (prior tobacco use) + 0.376 x (number of devices >2) + 0.016 x

48 an open fire (1.32; 1.22-1.43) and maternal tobacco use (1.23; 1.18-1.27).

49 (1.90 [1.38-2.62]; p<0.0001), and smokeless tobacco use (1.32 [1.03-1.69]; p=0.030) than in HIV-nega

50 than 50 years [5.19, (3.05-8.29)]; previous tobacco use [1.40 (1.18-1.66)]; and complicated initial

51 ascular disease (2.4% versus 3.3%; P=0.002), tobacco use (36.5% versus 52.3%; P<0.001), and prior car

52 ; lipid disorders, 12%-21%; diabetes, 4%-7%; tobacco use, 5%-16%; and obesity, 4%-9%).

53 with older age, cytotoxic chemotherapy, and tobacco use; 75% of survivors had symptomatic improvemen

54 A more ambitious target on tobacco use (a 50% reduction) will almost reach the targ

55 Tobacco use, a primary HNSCC risk factor, was evaluated

56 persistent opioid use included preoperative tobacco use (adjusted odds ratio [aOR], 1.35; 95% CI, 1.

57 that clinicians ask all pregnant women about tobacco use, advise them to stop using tobacco, and prov

58 ommends that clinicians ask all adults about tobacco use, advise them to stop using tobacco, and prov

59 essation before LTx were at greatest risk of tobacco use after LTx.

60 spective study, we describe the frequency of tobacco use after lung transplantation (LTx), pretranspl

61 Tobacco use after solid organ transplantation is associa

62 gestational weight gain, high underlying BP, tobacco use, alcohol consumption, and sedentary lifestyl

63 hnicity, body mass index, physical activity, tobacco use, alcohol consumption, formal education, clin

64 lmonary disease and coronary artery disease, tobacco use, alcohol use, and body mass index were also

65 ultiple measures of socioeconomic status and tobacco use, alcohol use, diet, and physical activity.

66 Pooled prevalence estimates of current tobacco use, alcohol use, low fruit and vegetable intake

67 d with a cluster of behavioural factors (ie, tobacco use, alcohol, diet, physical activity, and sodiu

68 ing was associated with an increased risk of tobacco use among adolescent offspring.

69 We assessed the prevalence of tobacco use among people living with HIV in LMICs.

70 er, very little is known about the extent of tobacco use among people living with HIV in low-income a

71 Tobacco use among people living with HIV results in exce

72 r brief counseling, to prevent initiation of tobacco use among school-aged children and adolescents.

73 -feasible interventions for the cessation of tobacco use among school-aged children and adolescents.

74 y, and the potential to create a new form of tobacco use among those no longer interested in taking u

75 rent tobacco use (smoked, smokeless, and any tobacco use) among 6729 HIV-positive men from 27 LMICs (

76 the potential ENDS have to alter patterns of tobacco use and affect the health of the public; however

77 Although the most important risk factors are tobacco use and alcohol consumption, the disease is also

78 e to use or problem use, as were alcohol and tobacco use and disorders, major depression, and schizot

79 tand the cancer risks of exclusive smokeless tobacco use and dual use of smokeless tobacco with other

80 Prevention and management of tobacco use and exposure to second-hand smoke in pregnan

81 Previous studies on smokeless tobacco use and head and neck cancer (HNC) have found in

82 onally representative, longitudinal study of tobacco use and health in the United States.

83 tween 2003 and 2014 from 28 LMICs where both tobacco use and HIV test data were made publicly availab

84 er of lifetime oral sexual partners, current tobacco use and immunosuppression.

85 l strategies that have significantly reduced tobacco use and initiation in the United States.

86 Excessive proteolysis occurs with chronic tobacco use and is causative for bronchiectasis and emph

87 by the reversal of socioeconomic gradients; tobacco use and low fruit and vegetable intake have beco

88 l groups; and was partially accounted for by tobacco use and mean arterial pressure.

89 They also had increased tobacco use and more comorbidities.

90 phic characteristics, lifestyle (alcohol and tobacco use and physical activity), and medication, were

91 ncluded studies presented clear patterns for tobacco use and physical activity, heterogeneity between

92 insomnia, asthma, rhinitis, weight, height, tobacco use and physical activity.

93 Goal 3, setting a global target of reducing tobacco use and premature mortality from non-communicabl

94 The possibility of a causal link between tobacco use and psychosis merits further examination.

95 mprove health behaviors (for example, reduce tobacco use and sedentary behavior and improve diet) of

96 20 years of age were queried regarding their tobacco use and serum cotinine was measured.

97 a diagnosis of bladder cancer on patterns of tobacco use and smoking cessation among patients with in

98 iovascular risk factors, as well as reducing tobacco use and substance abuse, should be leading prior

99 se correlation between a person's history of tobacco use and susceptibility to developing Parkinson's

100 king current perceptions of service members' tobacco use and unmasking the forces perpetuating those

101 obacco smoking, 3.4% (1.8-5.6) for smokeless tobacco use, and 27.1% (22.8-31.7) for any tobacco use.

102 obacco smoking, 2.1% (1.1-3.4) for smokeless tobacco use, and 3.6% (95% CI 2.3-5.2) for any tobacco u

103 e pulmonary disease, valvular heart disease, tobacco use, and alcohol abuse.

104 alence ratios for tobacco smoking, smokeless tobacco use, and any tobacco use separately for males an

105 other vegetables, age, sex, race/ethnicity, tobacco use, and caffeine.

106 d the health risks associated with nicotine, tobacco use, and electronic nicotine delivery systems in

107 f traditional risk factors (such as obesity, tobacco use, and genetic predisposition) and HIV-specifi

108 ms, hiatal hernia, elevated body mass index, tobacco use, and intra-abdominal distribution of fat) to

109 leep disturbance, heavy alcohol use, current tobacco use, and larger initial opioid prescription size

110 microcatheter type, smoking history, active tobacco use, and other risk factors for arterial disease

111 s, obesity, dyslipidemia, drug dependence or tobacco use, and renal disease.

112 ociated with early initiation of alcohol and tobacco use, and rs6495309 has been associated with nico

113 ace/ethnicity, education, employment status, tobacco use, and scanner technology.

114 ng for sex, race, education, income, region, tobacco use, and select chronic medical conditions (0-1

115 lant patient characteristics associated with tobacco use, and the safety, efficacy, and outcomes of p

116 perative group clinical trials do not assess tobacco use, and there is no observable trend in improve

117 residence, applicator license type, chewing tobacco use, and total lifetime days of all pesticide us

118 Smokeless tobacco use appears to be associated with HNC, especiall

119 se health effects of intermittent water pipe tobacco use are critical to strengthen the evidence base

120 Rates of dual and poly-tobacco use are high among trainees, and while these gro

121 prevent initiation and promote cessation of tobacco use are needed to reduce associated morbidity an

122 ng suboptimal diet, physical inactivity, and tobacco use, are leading causes of preventable diseases

123 history, systemic co-morbidities, alcohol or tobacco use as well as serum levels of calcium and vitam

124 similar in magnitude to that associated with tobacco use, as compared with no use (hazard ratio, 1.54

125 tors, including excess sugar consumption and tobacco use, as well as underlying infection and inflamm

126 Cooperative Group Program were evaluated for tobacco use assessment at enrollment and follow-up by us

127 The purpose of this study was to evaluate tobacco use assessment in patients enrolled onto activel

128 al laboratories as well as for point-of-care tobacco use assessment.

129 ace and ethnicity or those with a history of tobacco use, asthma, or diabetes mellitus type II.

130 ials reviewed, 45 (29%) assessed any form of tobacco use at enrollment, but only 34 (21.9%) assessed

131 Weight loss >= 5%, tobacco use at LEMS onset and age at onset >= 50 years w

132 Patients who reported active tobacco use at the time of PAVM embolization had a 5-yea

133 -demographic factors, CD4 count, alcohol and tobacco use, baseline WHO stage 4 disease, social suppor

134 As the risks of tobacco use become recognized and smoking becomes stigma

135 Respondents completed a survey on history of tobacco use, beliefs regarding bladder cancer risk facto

136 Stopping tobacco use benefits virtually every smoker.

137 ied according to centre, performance status, tobacco use, best response to previous EGFR tyrosine-kin

138 nts also reveal hidden relationships between tobacco use, body mass index, and blood pressure.

139 are effective measures to reduce alcohol and tobacco use, but are not available to target illicit dru

140 This study hypothesized that tobacco use by PAD patients would be associated with hig

141 Methamphetamine and/or tobacco use by pregnant women remains prevalent.

142 ints were biomarker-calibrated self-reported tobacco use by the mother at late pregnancy, birthweight

143 Tobacco use initiation; tobacco use cessation; health outcomes; harms.

144 health at age 38, even after controlling for tobacco use, childhood health, and childhood socioeconom

145 Age, sex, race/ethnicity, tobacco use, chronic conditions, influenza vaccination,

146 Risk factors include tobacco use, coronary artery disease, and respiratory fa

147 ssued a separate recommendation statement on tobacco use counseling in adults and pregnant women.

148 archers should use caution when interpreting tobacco use data obtained from check-all-that-apply form

149 rable changes in lifestyle such as increased tobacco use, decreased physical activity, and consumptio

150 Linear regression adjusted for income, tobacco use, dental insurance, and previous radiation an

151 , if risk factor targets for blood pressure, tobacco use, diabetes mellitus, and obesity are achieved

152 ce/ethnicity, and income level), alcohol and tobacco use, diabetes mellitus, and past periodontal tre

153 Tobacco use did not change significantly, but the 10-yea

154 , P < 10(-30)), followed by individuals with tobacco use disorder (TUD) (AOR = 8.222 ([7.925-8.530],

155 was significantly inversely associated with tobacco use disorder comorbidities (adjusted odds ratio

156 and caffeine withdrawal syndromes, aligning tobacco use disorder criteria with other substance use d

157 Tobacco use disorder is associated with dysregulated neu

158 ission and enhancing IC during the course of tobacco use disorder treatment.

159 ne the co-occurrence of past-year alcohol or tobacco use disorder with past-year anxiety disorders, m

160 rders, largely driven by an association with tobacco use disorder.

161 among those who met criteria for a past-year tobacco use disorder.

162 ase; 6) hyperlipidemia; 7) alcohol abuse; 8) tobacco use disorder; and 9) random effect of geographic

163 tudy of Nicotine Dependence (ascertained for tobacco use disorder; n = 918 cases; 988 control subject

164 es associated with alcohol use disorders and tobacco use disorders among heterosexual, bisexual, and

165 nly seven trials (4.5%) assessed any form of tobacco use during follow-up.

166 nicotine replacement therapy, and smokeless tobacco use during pregnancy are associated with cogniti

167 fluid balance, obesity, hypoxemia, acidosis, tobacco use, emergent hematoma evacuation, and vasopress

168 which might include behaviors such as lesser tobacco use, greater physical activity, and/or enhanced

169 art failure, peripheral arterial disease, or tobacco use had the largest predicted differences in sur

170 Substantial evidence suggests that tobacco use has adverse effects on cancer treatment outc

171 Tobacco use has fallen in countries that are members of

172 ent outcomes; however, routine assessment of tobacco use has not been fully incorporated into standar

173 To date, most genetic association studies of tobacco use have been conducted in European American sub

174 ets for reducing systolic blood pressure and tobacco use have more substantial effects on future scen

175 t were relevant to primary care and reported tobacco use, health outcomes, or harms were included.

176 l concentrated among patients with diabetes, tobacco use, heart failure, or peripheral arterial disea

177 s for SCD: older age, African-American race, tobacco use, higher pulse, higher waist-to-hip ratio, el

178 icantly associated with STAT3 activation and tobacco use history in non-small cell lung cancer (NSCLC

179 ients with diabetes (HR, 0.88), a history of tobacco use (HR, 0.82), heart failure (HR, 0.84), and pe

180 RNA (HR, 1.19 [95% CI, 1.02-1.38], P = .02), tobacco use (HR, 1.37 [95% CI, 1.02-1.85], P = .04), CD4

181 Among patients with ERAF, only current tobacco use (HR, 3.84; 95% CI, 1.82-8.11; P<0.001) was a

182 has in the past been largely associated with tobacco use, human papillomavirus (HPV+) oropharynx canc

183 Age, sex, tobacco use, hypercholesterolemia, hypertension, and typ

184 odels included adjustment for race, obesity, tobacco use, hypertension (HTN), atrial fibrillation (AF

185 antly to the global burden of CVD, including tobacco use, hypertension, and secondary prevention for

186 ed annual 480 000 deaths are attributable to tobacco use in adults, including from secondhand smoke.

187 s on the rates of initiation or cessation of tobacco use in children and adolescents and on health ou

188 sociated with an increased risk of offspring tobacco use in later life.

189 otential for creating an alternative form of tobacco use in light of declining cigarette sales and so

190 acco industry's future depends on increasing tobacco use in low-income and middle-income countries (L

191 nificantly higher smoking and male smokeless tobacco use in most Appalachian disparity states.

192 ically associated with the long-term risk of tobacco use in offspring.

193 Tobacco use in PAD is associated with substantial increa

194 INTERPRETATION: The high prevalence of tobacco use in people living with HIV in LMICs mandates

195 weden 2005-2012 with information on maternal tobacco use in pregnancy, followed until December 2015.

196 Pooled prevalence of any tobacco use in pregnant women in LMICs was 2.6% (95% CI

197 Overall, tobacco use in pregnant women in LMICs was low; however

198 We assessed the magnitude of tobacco use in pregnant women in LMICs.

199 However, the extent of tobacco use in pregnant women in low-income and middle-i

200 The pooled prevalence of current smokeless tobacco use in pregnant women was lowest in the European

201 nction as a potential mechanism for elevated tobacco use in schizophrenia and also identify activatio

202 ng education or brief counseling, to prevent tobacco use in school-aged children and adolescents have

203 r brief counseling, to prevent initiation of tobacco use in school-aged children and adolescents.

204 never having smoked a full cigarette, and no tobacco use in the prior 3 years.

205 etween maternal smoking during pregnancy and tobacco use in young adulthood, an association that was

206 ed model regarding the effects of emotion on tobacco use, in particular, as well as on addictive beha

207 ctors associated with poly-tobacco (vs. mono-tobacco) use included lower confidence to remain tobacco

208 ities for significantly reducing the toll of tobacco use, including: (1) the need for novel, nonlinea

209 ny cancer cases in India are associated with tobacco use, infections, and other avoidable causes.

210 fair-quality) that were designed to prevent tobacco use initiation or promote cessation (or both) an

211 Tobacco use initiation; tobacco use cessation; health ou

212 406 loci associated with multiple stages of tobacco use (initiation, cessation, and heaviness) as we

213 cological interventions with no or a minimal tobacco use intervention control group (eg, usual care,

214 Tobacco use is a leading cause of preventable death worl

215 Tobacco use is a major driver of carcinogenesis in HNSCC

216 ctive, one beneficial consequence of chronic tobacco use is a reduced risk for Parkinson's disease.

217 Tobacco use is an established risk factor for the develo

218 Tobacco use is an important preventable cause of periphe

219 Tobacco use is an underappreciated risk for Barrett's es

220 First, that daily tobacco use is associated with an increased risk of psyc

221 Daily tobacco use is associated with increased risk of psychos

222 but whether or not they help people to quit tobacco use is controversial.

223 vernments can create an environment in which tobacco use is reduced and citizens maintain good levels

224 Tobacco use is responsible for a large proportion of the

225 Tobacco use is the leading cause of preventable death in

226 Tobacco use is the leading cause of preventable death in

227 Tobacco use is the leading preventable cause of death wo

228 Tobacco use is the leading preventable cause of mortalit

229 Tobacco use is the main risk factor for HNSCC, and tobac

230 tional individual level risk factors (mainly tobacco use, lipids, and elevated blood pressure) and so

231 e that health professionals have in reducing tobacco use, many have a smoking habit themselves.

232 Furthermore, antipsychotics and tobacco use may increase CB1R availability in this popul

233 that disparities in hypertension related to tobacco use might be masked by differences in body mass

234 ionally representative sources that measured tobacco use (n = 2102 country-years of data) were system

235 rovides evidence-based policies for reducing tobacco use, no global policy exists for the control of

236 x (BMI), hypertension, diabetes, alcohol and tobacco use, ocular conditions (including blindness, cat

237 ctors for developing colon pathology include tobacco use (odds ratio (OR), 2.0; 95% confidence interv

238 n integral role in affecting the patterns of tobacco use of those newly diagnosed.

239 accurately understand the precise effect of tobacco use on cancer treatment outcomes.

240 f coronary artery disease, but the impact of tobacco use on cardiac structure and function in the gen

241 total and direct causal roles of alcohol and tobacco use on CVD risk factors and events.

242 t the effect of comorbid methamphetamine and tobacco use on human fetal brain development.

243 alth (nutrition, environment/occupation, and tobacco use) on day 2.

244 r point, 1.92; 95% CI, 1.55-2.37; P < .001), tobacco use (OR, 3.64; 95% CI, 1.36-9.73; P = .01), ence

245 nt with offspring's smoking, age at onset of tobacco use, or changes in use between 2006 and 2010.

246 dence intervals for the associations between tobacco use, oral health indicators, and PD risk.

247 e likely to report initiation of combustible tobacco use over the next year.

248 ependent of age, diabetes, hypertension, and tobacco use (P < 0.001).

249 , more years on dialysis before waitlisting, tobacco use, panel-reactive antibody greater than 0, pub

250 As tobacco use patterns continue to change and diversify, f

251 nmental factors, such as risk perceptions of tobacco use, peer use, and tobacco-company influences.

252 from a short list of risk factors--including tobacco use, poor diet and physical inactivity (both str

253 re found to be significantly associated with tobacco use posttransplant.

254 Four percent of our LTx cohort resumed tobacco use posttransplant.

255 In conclusion, the genetics of alcohol and tobacco use potentially has broader implications on phys

256 pressure, heart rate, change in heart rate, tobacco use, presence of diabetes mellitus, alcohol use,

257 The difference in smokeless tobacco use prevalence between HIV-positive and HIV-nega

258 e to preventive practices from 1999 to 2010, tobacco use remained high, and almost half of U.S. adult

259 Combustible tobacco use remains the number-one preventable cause of

260 Tobacco use remains the single most common modifiable ca

261 had 100% sensitivity and 45% specificity for tobacco use resumption.

262 The PCI may be a useful predictor of tobacco use resumption.

263 higher prevalence in HIV-positive men of any tobacco use (risk ratio [RR] 1.41 [95% CI 1.26-1.57]) an

264 hypertension, diabetes, hyperlipidemia, and tobacco use, risk differences comparing participants wit

265 gher prevalence in HIV-positive women of any tobacco use (RR 1.36 [95% CI 1.10-1.69]; p=0.0050), toba

266 formation on several risk factors, including tobacco use, secondhand exposure to cigarette smoke, obe

267 acco smoking, smokeless tobacco use, and any tobacco use separately for males and females to study di

268 Using serum cotinine values to classify tobacco use showed that smokers have higher serum concen

269 Prevalence of current tobacco use (smoked and smokeless) was estimated for eve

270 regional, and overall prevalence of current tobacco use (smoked, smokeless, and any tobacco use) amo

271 ression analyses, adjusted for education and tobacco use (snuff use in the smoking analysis and smoki

272 ic blood pressure, diastolic blood pressure, tobacco use, statin use, body mass index, urine microalb

273 participants without a history of alcohol or tobacco use, suggesting that observed associations with

274 ed minority adults surveyed in the 1992-2015 Tobacco Use Supplement to the Current Population Survey

275 rictions, augmenting access to treatment for tobacco use through insurance coverage and telephone hel

276 ourth priority is a UN high-level meeting on tobacco use to galvanise global action towards the 2040

277 amples is of great importance to testing for tobacco use, tobacco cessation treatment, and studies on

278 However, global efforts to control smokeless tobacco use trail behind the progress made in curbing ci

279 Parties collect or present data on smokeless tobacco use under global or national surveillance mechan

280 Older age, tobacco use, underlying cardiovascular disease, diabetes

281 Behavioural risk factors, including tobacco use, unhealthy diets, and physical inactivity ar

282 oeconomic status and harmful use of alcohol, tobacco use, unhealthy diets, and physical inactivity wi

283 Reductions in tobacco use, uptake of preventive measures, adoption of

284 ong children in the US since the late 1990s, tobacco use via electronic cigarettes (e-cigarettes) is

285 We found that tobacco use was associated with a lower risk of PD in ma

286 Unlike cannabis use, tobacco use was associated with worse lung function, sys

287 Tobacco use was observed to be associated with a lower r

288 ation and treatment of individuals who smoke tobacco using water pipes.

289 complications, high triglyceride levels, and tobacco use were additional independent predictors for g

290 ger lesion size, nonupper lobe location, and tobacco use were associated with increased diagnostic yi

291 Marijuana and tobacco use were each independently associated with high

292 en, hospital stays in the past 6 months, and tobacco use were included, the adjusted HR was 0.73 (95%

293 A high body mass index and current tobacco use were the only independent risk factors for d

294 cotine and cotinine in hair as biomarkers of tobacco use where in the past the detection of cotinine

295 nary function and other covariates including tobacco use, which was analyzed in parallel as a positiv

296 been described, including chronic heartburn, tobacco use, white race, and obesity.

297 older, peripheral artery disease, diabetes, tobacco use, white race, stroke, atrial fibrillation, co

298 er, education, tooth brushing, flossing, and tobacco use with a questionnaire.

299 ppressants and other medications, and 4% for tobacco use, with 31% clinic appointment nonadherence in

300 Prohibiting tobacco use would be entirely consistent with other mili